New incident report
Incident Report Number: 2020-2303
Registrant Reference Number: 2020-CA-000002
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: UNKNOWN
PMRA Registration No. 29930 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard OneSpot Flea and Tick Cat Drops
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Animal's Owner
Cat / Chat
Domestic Shorthair
1
Female
0.7
6
lbs
Skin
>1 wk <=1 mo / > 1 sem < = 1 mois
>24 hrs <=3 days / >24 h <=3 jours
System
Unknown / Inconnu
No
No
Unknown/Inconnu
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 29-Dec-2019, an 8 month old, approximately 6 pound, intact, female, Domestic Shorthair cat, in unknown condition, with no known concomitant medical conditions, was administered 1 tube of Hartz UltraGuard OneSpot Flea and Tick Cat Drops (S-Methoprene) via the topical route by the animal owner. On 01-Jan-2020, the cat developed application site pruritus, application site erythema, application site alopecia, and application site bleeding. An unknown amount of unspecified antibiotic cream, was applied to the affected area, via the topical route by the animal owner. On approximately 03-Jan-2020, the cat developed a scab at the application site. On 06-Jan-2020, the cat continued to scratch at the application site, causing the scab to break open, resulting in bleeding.The cat was not evaluated by a veterinarian, no treatment was performed and the signs persisted at the time of the call. Veterinary evaluation was recommended. No further information was received in this case.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.